This gives far more credibility in the medical & scientic community for MXC R&D into medications, with the end goal of licensing. It’s not going to bring revenue stat, but part of the process to bring this. If people don’t understand the need I suggest you look at TGA SAS & C pathway to understand what is happening now for Cannepil. I had a sticky beak at HL Pharma on the weekend & they have a licence to import & distribute Medical Cannabis & SAS C pathway drugs.
To see this on PBS would just be fantastic for Epilepsy sufferers, to be able to go to their local pharmacy & get what they need, instead of travelling hundreds of kms to a major trial site to collect their medicine on SAS from a hospital pharmacy. I see this as a big positive. Early stage biotech as I said in another post this morning. Even big Pharmas go through this being registered on TGA for high cost drugs via SAS prior to PBS on open label ph 3 trials . I would rank Cannepil in the lower to medium cost range at an estimate of A$800 a month. A positive ANN on credibility, which is much needed here after recent events. Not so much on the revue side of things. Cannepil will be good.
